Summary by Moomoo AI
TENSENG PHARMACEUTICALS - B (BRII-B) ANNOUNCED ITS RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023, WITH BANK DEPOSITS AND CASH DOWN 11.3% AND R&D EXPENDITURE DOWN 8.6% DUE TO THE TERMINATION OF COVID-19 PROJECTS. Other income increased 51.7%, driven by higher deposit rates. The company actively promoted the hepatitis B virus project and acquired all intellectual property rights to BRII-179 in February 2024 to increase its production capacity. In the future, post-clinical trials of HBV functional cure projects will be launched and external cooperation will be sought to advance MDR/XDR, HIV and CNS projects. The company realigns its executive team, optimizes resource allocation, maintains a stable cash reserve to support long-term operations.